3.5.4.4	(+)-erythro-9-(2-hydroxy-3-nonyl)adenine	specific inhibitor of ADA1	163510	
3.5.4.4	(+)-erythro-9-(2-hydroxy-3-nonyl)adenine	-	163510	
3.5.4.4	(2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[3-(trifluoromethyl)phenyl]pentan-2-ol	comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine	237480	
3.5.4.4	(2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[4-(trifluoromethyl)phenyl]pentan-2-ol	comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine	237481	
3.5.4.4	(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol	-	42126	
3.5.4.4	(S)-(-)-epoxydecane	-	132683	
3.5.4.4	1,6-Dihydro-6-(hydroxymethyl)purine riboside	-	90438	
3.5.4.4	1-(4-benzylphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea	-	74003	
3.5.4.4	1-(4-fluorophenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea	-	74000	
3.5.4.4	1-(4-methoxyphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea	-	73999